Recombinant Human SIGLEC7 Protein，His

Siglec-7, or sialic acid-binding immunoglobulin-like lectin 7, is a member of the Siglec family of proteins, which are known to play critical roles in immune regulation and cell signaling. It is predominantly expressed on the surface of immune cells, particularly natural killer (NK) cells and certain myeloid cells, where it interacts with sialic acid-containing glycans on neighboring cells. This interaction can modulate immune responses, influencing processes such as cell activation, proliferation, and apoptosis. The study of Siglec-7 has gained significant attention due to its potential implications in various pathological conditions, including cancer and autoimmune diseases. In tumors, Siglec-7 expression can be upregulated, enabling malignant cells to evade immune surveillance by dampening responses from NK cells. Consequently, researchers have been investigating the production and characterization of recombinant Siglec-7 proteins to understand its structural features and ligand-binding properties better. These studies aim to elucidate the role of Siglec-7 in immune evasion and establish its potential as a therapeutic target. Recombinant Siglec-7 proteins can be utilized in assays to screen for small molecules or antibodies that can block its interactions with sialylated ligands, potentially enhancing antitumor immunity. Overall, research into recombinant Siglec-7 is pivotal for developing novel immunotherapeutic strategies that could improve outcomes in cancer treatment and other diseases associated with immune dysregulation.